Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_assertion type Assertion NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_head.
- NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_assertion description "[Although the first Moss study reported a significant improvement in respiratory function (FEV(1)) 30 days after participants had received their first dose of gene therapy agent, this finding was not confirmed in their larger second study or in our meta-analysis.In participants who received the CFTR gene transfer agents in the Alton study, `influenza-like` symptoms were found (relative risk 7.00 (95% confidence interval (CI) 1.10 to 44.61)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_provenance.
- NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_assertion evidence source_evidence_literature NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_provenance.
- NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_assertion SIO_000772 17443603 NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_provenance.
- NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_assertion wasDerivedFrom befree-20140225 NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_provenance.
- NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_assertion wasGeneratedBy ECO_0000203 NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_provenance.